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Abstract 
Burning mouth syndrome (BMS) has been considered an enigmatic condition because the intensity of pain rarely 
corresponds to the clinical signs of the disease. Various local, systemic and psychological factors are associated 
with BMS, but its etiology is not fully understood. Also there is no consensus on the diagnosis and classification of 
BMS. A substantial volume of research has been focused on BMS during the last two decades. Progress has been 
made but the condition remains a fascinating, yet poorly understood area, in the field of oral medicine. Recently, 
there has been a resurgence of interest in this disorder with the discovery that the pain of BMS may be neuropathic 
in origin and originate both centrally and peripherally. The aim of this paper is to explore the condition of BMS with 
the specific outcome of increasing awareness of the condition.
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Introduction
The patient with a complaint of a burning sensation of 
the oral mucosa presents one of the most difficult cha-
llenges to the health care professionals. There is a varie-
ty of names applied to this presentation including, but 
not limited to, burning mouth syndrome (the most wi-
dely accepted), stomatodynia, stomatopyrosis, glosso-
pyrosis, glossodynia, sore mouth, sore tongue and oral 
dysesthesia. Burning mouth syndrome (BMS) is defined 
by the International Association for the Study of Pain as 
burning pain in the tongue or other oral mucous mem-
brane associated with normal signs and laboratory fin-
dings lasting at least 4 to 6 months (1). The International 
Headache Society in the International Classification of 
Headache Disorders II classifies BMS in the category 
of cranial neuralgias and central causes of facial pain 
within the subcategory of central causes of facial pain 
(2). BMS is described as an intraoral burning sensation 
for which no medical or dental cause can be found. It is 
usually described as oral burning pain, sometimes with 
dysesthetic qualities similar to those present in other 
neuropathic pain conditions with the absence of clinical 
and laboratory abnormalities.
As a result of the variations in experienced symptoms, 
and despite the fact that numerous studies have been ca-
rried out, there is no universal consensus on the diag-
nosis, etiology and treatment of BMS. This leads to 
patients being referred from one health care professio-
nal to another, causing an increased burden on both the 
health care system and the patient (3). Various groups 
of investigators have attempted to provide an answer to 
the questions regarding this topic, which is the subject 
of considerable controversy. The multiplicity of factors 
related with this nosologic entity, which in one form or 
another are involved in the appearance of the symptoms 
have made it currently one of the most debated issues 
(4).
Epidemiology
The prevalence of burning mouth symptoms reported 
from international studies ranges from 0.7% to 4.6% 
(4). The considerable variation in prevalence among 
these studies may be because of different definitions of 
BMS leading to different criteria for the selection of the 
populations. It seems the prevalence of BMS increases 
with age in both males and females, with this syndrome 
mainly affecting females in the fifth to seventh decade 
(5). The mean age of BMS is between 55-60 years, with 
occurrence under 30 being rare (6,7). The ratio between 
females and males varies from 3:1 to 16:1 (8). These 
gender differences may be explained by biologic, psy-
chologic, and socio-cultural factors; however, these fac-
tors are yet to be defined. It seems from these epidemio-
logic studies that menopausal females have a particularly 
high incidence of burning mouth (9). This syndrome has 
never been described in children or adolescents. No stu-
dies exist in relation to any occupational, educational or 
social grouping (10).
Classification
There have been several proposed classification sche-
mes to better characterize and define BMS. One of the 
proposed classification is based on daily fluctuations of 
the symptoms (6,9)
a) Type 1: Characterized by progressive pain, patients 
wake up without pain, which then increases throug-
hout the day, affects approximately 35% of patients. 
This type may be associated with systemic diseases, 
such as nutritional deficiencies.
b) Type 2: Symptoms are constant throughout the day 
and patients find it difficult to get to sleep, represents 
55%. These patients usually present associated psy-
chological disorders.
c) Type 3: Symptoms are intermittent, with atypical 
location and pain. Constitutes 10% of patients. It 
seems that contact with oral allergens could play an 
important etiologic role in this group.
A more pragmatic approach is proposed by Scala et al. 
(4), who organize BMS into two clinical forms,‘Primary’ 
or Essential/ Idiopathic BMS, in which the causes can-
not be identified‘Secondary’ BMS, resulting from local 
factors or systemic conditions.
Thus, these idiopathic and secondary criteria form two 
different subgroups of the same pathology.
Etiopathogenesis
The etiology of BMS is poorly understood. Most su-
pport a multi-factorial syndrome involving the interac-
tion of biological and psychological systems. A number 
of etiologies have been proposed suggesting BMS in-
volves alterations in both central and peripheral nervous 
systems (11). The various factors related with the etio-
pathogenesis of this syndrome have been divided into 
local, systemic and psychological. (Table 1)
A) Local Factors:
One should consider physical, chemical or biological 
(some bacteria or fungi) factors which have a direct irri-
tant effect on the oral mucosa and are able to set off the 
burning symptoms (9). A mechanical factor to consider 
is the use of poorly fitting prostheses that produce micro-
trauma or local erythema. Local allergic reactions, due 
principally to high levels of residual monomers should 
also be considered. Infection by Candida albicans has 
been considered one of the most frequent factors in the 
production of BMS (10). Xerostomia is a concomitant 
symptom in patients with BMS, prevalence varying bet-
ween 34 and 39% (12). In recent years investigations 
have been carried out into the alterations in taste percep-
tion and tolerance to pain as a possible cause of the bur-
ning sensation. This theory proposes that certain people, 
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labeled as supertasters due to the high density of fun-
giform papillae present on the anterior part of the ton-
gue, are more susceptible to developing burning mouth 
pain. Supertasters are principally women, and are able 
to perceive the bitter taste of a substance called PROP 
(6-n-propiltiouracilo) (4,5,9).
B) Systemic Factors:
Systemic factors implicated in BMS; many of these are 
deficiencies, such as vitamin deficiencies (vitamin B12, 
B6, C and folic acid), anemias and low levels of zinc. 
Hormonal changes (reduced plasma estrogens), diabetes 
mellitus, hypothyroidism and immunological diseases 
have also been described. Many medications are intima-
tely related with burning mouth; among which are found 
antihistamines, neuroleptics, some antihypertensives, 
antiarrhythmics and benzodiazepines. Antihypertensi-
ves are among the most frequently implicated medici-
nes, principally those that act on the renin-angiotensin 
system (13).
C) Psychological Factors:
Studies exist that suggest that psychopathologic factors 
may play an important role in BMS and support the mul-
tifactorial etiology (14,15). Many of these patients have 
symptoms of anxiety, depression and personality disor-
ders, and it has been demonstrated that patients with 
BMS have a greater tendency towards somatization and 
other psychiatric symptoms (16). Cancerphobia can be 
present in up to 20-30% of these patients. A lower le-
vel of socialization and higher levels of somatic anxiety 
have been observed, as well as muscular tension, a hig-
her tendency to worry about health and greater sadness. 
BMS is considered a chronic pain disorder that adver-
sely affects quality of life (17).
Clinical Presentation
In more than one half of patients with BMS, the onset 
of pain is spontaneous, with no identifiable precipitating 
factor. Approximately one third of patients relate time of 
onset to a dental procedure, recent illness or medication 
course. Regardless of the nature of pain onset, once the 
oral burning starts, it often persists for prolonged period 
of time (18). The predominant pain character reported 
by BMS patients is a prolonged ‘burning’ sensation of 
the oral mucosa described as moderate to severe intensi-
ty that may vary throughout the course of the day (4,19). 
The mean severity of pain has been assessed at about 
5-8cm on a 10cm visual analogue scale, where 0cm re-
presents ‘no pain’ and 10 cm corresponds to the ‘worst 
possible pain’ (20) (Table 2).
ETIOLOGIC FACTORS (9)
LOCAL 
Poorly fitting prosthesis
Dental treatment
Parafunctional habits- Clenching, Bruxism,
Allergic contact stomatitis
Taste Alterations
Infection- Bacterial, Fungal, Viral
Xerostomia
SYSTEMIC 
Endocrine- Hypothyroidism, Menopause, Diabetes
Deficiencies- Iron, Vitamin B complex, Zinc
Anemia
Medications
Sjogren’s Syndrome
Esophageal reflux
PSYCHOLOGIC 
Anxiety
Depression
Compulsive disorders
Cancerphobia
IDIOPATHIC FACTORS
Table 1. Etiologic factors for burning mouth syndrome.
CLINICAL FEATURES (13)
Unilateral or bilateral burning pain localized to tongue, 1. 
palate, lips and gingiva
Pain that gets worse over the day2. 
Decreased pain on eating3. 
Decreased pain with sleep4. 
Absence of clinical finding5. 
Presence of abnormal or dysgeusic tastes, usually meta-6. 
llic, bitter or sour
Complaint of dry mouth in presence of normal flows7. 
Sensory changes or parasthesias including complaints of 8. 
areas of roughness or irritation
Table 2. Clinical features that are helpful in the diagnosis of burning 
mouth syndrome.
The burning sensation often occurs in more than one 
oral site, with the anterior two thirds of the tongue, the 
anterior hard palate and the mucosa of the lower lip most 
frequently involved (21). Most studies have found that 
oral burning is frequently accompanied by other symp-
toms, including dry mouth and altered taste (21). Altera-
tions in taste occur in as many as two thirds of patients 
and often include complaints of persistent tastes (bitter, 
metallic, or both) or changes in the intensity of taste per-
ception. Damage to the taste has been reported in asso-
ciation with BMS, because of disinhibition of pain sig-
naling (7). Dysgeusic tastes accompanying oral burning 
are often reduced by stimulation with food. Facial skin 
is not usually affected. In many patients with the syndro-
me, pain is absent during the night but occurs at a mild to 
moderate level by middle to late morning. Patients often 
report that the pain interferes with their ability to fall 
asleep. Perhaps because of sleep disturbances, constant 
pain, or both, patients with oral burning pain often have 
mood changes, including irritability, anxiety and depres-
sion (22). The location of oral pain is most commonly 
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bilateral and importantly does not follow the anatomical 
distribution of a peripheral sensory nerve (23).
Minimal information is available on the natural course 
of the condition. In most cases the syndrome follows a 
protracted course with an average duration of 3.4years 
but may last for 12 years or more with recovery in upto 
two-thirds of patients within 6-7 years of onset (5, 11). It 
has also been reported that BMS has a negative impact 
on health-related quality of life of individuals (24).
Diagnosis
Taking a thorough and comprehensive history is the key 
to diagnosis of BMS. Important information to be ascer-
tained by the practitioner relates to the past and current 
symptoms (pain, dry mouth, taste), their duration, inten-
sity, character, location, onset, and factors that improve 
or worsen the pain and its course. A numeric or visual 
analog scale measuring the patient’s pain intensity and 
dry mouth should be used. Information should be ob-
tained about current and past health status, including 
chronic systemic disorders, allergies, and immunologic 
disorders, and previous and current medications. This 
history should also include information on previous or 
current psychosocial stressors and psychologic well be-
ing. Important clinical characteristics that would provide 
a diagnosis of BMS are: a sudden or intermittent onset 
of pain usually localized to the tongue, hard palate, and 
lips; bilateral presentation; a persistent and often pro-
gressive increase in pain during the day often not pre-
sent on awakening and the remission of pain with eating 
and sleeping; subjective sensations of a dry mouth and 
intraoral areas of roughness, irritation, or swelling and 
parafunctional habits (14).
The clinical examination is more to rule out any possible 
local factors that may be responsible for the oral burning 
complaints. The clinical examination should include an 
extra-oral and intraoral examination of temporomandi-
bular joint function; inspection and palpation of the mas-
ticatory muscles, oral mucosa, tongue mobility, and den-
tal hard and soft tissues; and evaluation of any prosthetic 
devices. Objective measurements of salivary flow rates 
(whole stimulated and unstimulated saliva) and taste 
function should be taken (25). Neurologic imaging and 
consultation should be a consideration if patients present 
with more complex, confounding, or atypical symptoms, 
including sensory, motor, and autonomic changes, to rule 
out any neurodegenerative disorders or central nervous 
system pathology (9) (Table 3).
The diagnosis is usually late, often due to a lack of un-
derstanding of the nature of this entity, in addition to 
the patients taking up many health resources, since they 
frequently consult various specialists. It is important to 
highlight that the diagnosis of BMS should be establis-
hed only when all other possible causes have been dis-
counted, being a diagnosis by elimination (10).
Treatment
The management of BMS has been quite disappointing 
to date – this in part being due to our lack of knowled-
ge of the specific mechanisms underlying the syndrome. 
The symptoms of BMS tend to become chronic. This 
complicates patient management and gives rise to sit-
uations similar to those found in chronic pain, where 
symptoms persistence over time gives rise to increased 
anxiety and depression. Paramount to the clinical mana-
gement of BMS is obtaining the correct diagnosis. Also, 
it has been proved that the sooner treatment is prescribed 
after the diagnosis of burning mouth syndrome (BMS), 
the better the results obtained (26).
Initially, the clinician must determine if the patient is 
suffering from primary BMS or secondary BMS (27). 
Secondary BMS requires appropriate diagnosis and 
treatment of the underlying condition to manage symp-
toms. In primary BMS the cause is unclear, so treatment 
options are based on patients’ symptomatology. Three 
approaches or combinations that can be considered part 
of the management strategy include topical medications, 
systemic medications and behavioral interventions (9) 
(Table 4).
The most-used medications to treat this syndrome are 
antidepressants, antipsychotics, antiepileptics, analge-
sics and oral mucosa protectors. The tricyclic antide-
pressants such as amitriptyline and nortriptyline at low 
CLINICAL TEST (8, 13)
HEMATOLOGIC TESTS
Complete blood count
Glucose levels
Nutritional factors
Autoimmune panel
ORAL CULTURES
Fungal, Viral or Bacterial (if suspected)
IMAGING
MRI, CT scans & Nuclear medicine (to rule out central 
changes or patient is not responding to medication)
SALIVARY FLOW RATES
Unstimulated (0.3–0.4 g/min)
Stimulated (0.75–2.0 g/min)
SALIVARY UPTAKE SCANS
If low salivary flow rates and Sjogren syndrome suspected
ALLERGY TESTING
If needed, especially for a dental panel & allergens
TRIAL OF DISCONTINUATION OF CERTAIN MEDICA-
TIONS
Including ACE inhibitors
GASTRIC REFLUX STUDIES
MRI: Magnetic Resonance Imaging
CT: Computed Tomography
g/min: Grams/minute, 
ACE: Angiotensin Converting Enzymes
Table 3. Clinical tests for burning mouth syndrome.
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doses are useful in BMS, although some authors contra-
indicate their use in patients with dry mouth as they can 
worsen the condition (10). Studies have been made to 
evaluate the efficacy and tolerance of amisulpiride (50 
mg/day) and selective serotonin inhibitors: paroxetine 
(20 mg/day) and sertraline (50 mg/day) in the treatment 
of BMS, over eight weeks, with a reasonably high effica-
cy (around 70%) (28). The efficacy of oral clonazepam 
(0.25 mg/day increasing increasing to a maximum of 3 
mg/day) has also been evaluated with variable results, or 
by topical application (0.5 mg to 1 mg two or three times 
a day) with better results (29).
Gabapentin has demonstrated mixed results and studies 
are ongoing with pregabalin. The medication is adminis-
tered at an initial dose of 300 mg/day, increasing by 300 
mg/day every two days to a maximum of 2,400 mg/day 
(30, 31). Topical capsaicin has also been applied in BMS, 
used as a desensitizing agent in patients with BMS, but 
it is usually unaccepted by patients due to its taste. To-
pical capsaicin has been used as a treatment alternative 
for controlling neuropathic pain in general. The drug is 
normally used at concentrations of between 0.025% and 
0.075%, inducing desensitization to thermal, chemical 
and mechanical stimuli when applied topically. Howe-
ver, it should be noted that there are clear limita tions to 
the use of topical capsaicin, such as limited effect over 
time and a limited magnitude of improvement (32). Sys-
temic capsaicin has been used (0.25%, three times a day, 
for 30 days) with a significant reduction in pain intensity 
compared with a placebo group (33).
Alpha lipoic acid is a powerful neuroprotector that pre-
vents damage to nerve cells by free radicals. It signifi-
cantly reduces the symptoms in the majority of patients 
with idiopathic dysgeusia. Several studies suggest that 
alpha lipoic acid can improve the symptoms in BMS, 
showing that at two months, 97% of the patients treated 
with alpha lipoic acid (200 mg, three times a day) expe-
rienced an improvement in the symptoms (34).
Topical steroid hormones and anti-inflammatory rinses 
have been tried with little evidence of effectiveness in 
reducing or eliminating the symptoms of burning mouth 
syndrome, particularly when compared to placebo or 
spontaneous remission rates (35).
Hormone replacement therapy (HRT) has also been 
used, finding that women with symptoms of burning and 
estrogen receptors in the oral mucosa respond to hor-
mone replacement, while this does not occur in patients 
without these receptors; however it cannot be guaran-
teed that HRT could be an effective treatment for the oral 
symptomatology (10).
Studies on the effect of cognitive therapy on resistant 
BMS shows a statistically significant reduction in pain 
intensity for those receiving cognitive therapy compared 
with placebo immediately following the therapy and a 
further reduction at the 6-month follow up (36). Ano-
ther study showed some improvement of BMS resulting 
from psychotherapy treatment over 2 months, with sig-
nificant improvement when combined with alpha-lipoic 
acid therapy (ALA) (600 mg/d) (37). It seems from the-
se studies that the practitioner may consider the invol-
vement of a behavioral medicine practitioner as part of 
a multidisciplinary approach when managing patients 
who have BMS.
Conclusions
Burning Mouth Syndrome remains a fascinating, though 
poorly understood, condition in the field of oral medi-
cine. No consensus exists in defining, diagnosing and 
treating BMS. Furthermore, the lack of understanding 
the cause and mechanism behind the syndrome adds to 
the difficulty in finding a therapeutic management pro-
gram. There is little evidence-based material to assist the 
practitioner when dealing with these individuals. There 
is no doubt that innovative and interdisciplinary research 
is required to elucidate and expand on the knowledge of 
the etiology and pathogenic factors involved in BMS. 
The positive aspect is that most patients can be helped 
and many achieve a complete cure of their condition. 
It relies, however, on initial recognition and this is the 
most critical step.
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